- Home
- KZR vs FSEA Comparison
KZR vs FSEA Comparison
Compare KZR & FSEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- FSEA
- Stock Information
- Founded
- KZR 2015
- FSEA 1890
- Country
- KZR United States
- FSEA United States
- Employees
- KZR N/A
- FSEA N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- FSEA Savings Institutions
- Sector
- KZR Health Care
- FSEA Finance
- Exchange
- KZR Nasdaq
- FSEA Nasdaq
- Market Cap
- KZR 54.1M
- FSEA 43.6M
- IPO Year
- KZR 2018
- FSEA N/A
- Fundamental
- Price
- KZR $6.45
- FSEA $10.25
- Analyst Decision
- KZR Hold
- FSEA
- Analyst Count
- KZR 2
- FSEA 0
- Target Price
- KZR $11.00
- FSEA N/A
- AVG Volume (30 Days)
- KZR 61.0K
- FSEA 10.8K
- Earning Date
- KZR 11-12-2024
- FSEA 11-08-2024
- Dividend Yield
- KZR N/A
- FSEA N/A
- EPS Growth
- KZR N/A
- FSEA N/A
- EPS
- KZR N/A
- FSEA N/A
- Revenue
- KZR N/A
- FSEA $11,390,000.00
- Revenue This Year
- KZR N/A
- FSEA N/A
- Revenue Next Year
- KZR N/A
- FSEA N/A
- P/E Ratio
- KZR N/A
- FSEA N/A
- Revenue Growth
- KZR N/A
- FSEA N/A
- 52 Week Low
- KZR $5.20
- FSEA $7.25
- 52 Week High
- KZR $11.40
- FSEA $10.38
- Technical
- Relative Strength Index (RSI)
- KZR 28.75
- FSEA 81.07
- Support Level
- KZR $6.80
- FSEA $9.25
- Resistance Level
- KZR $7.04
- FSEA $10.38
- Average True Range (ATR)
- KZR 0.24
- FSEA 0.25
- MACD
- KZR -0.06
- FSEA 0.11
- Stochastic Oscillator
- KZR 0.00
- FSEA 87.02
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About FSEA First Seacoast Bancorp Inc.
First Seacoast Bancorp Inc is a savings and loan holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank, in one-to-four-family residential real estate loans, commercial real estate, and multi-family real estate loans, acquisition, development and land loans, commercial and industrial loans, home equity loans and lines of credit and consumer loans. The company generates revenue from financial instruments, such as loans, letters of credit, and investment securities, as well as revenue related to mortgage servicing activities and bank-owned life insurance.